Oncology On targeted radiotherapeutics, with Marc Hedrick Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.
News Hutchmed scores with drug for rare autoimmune disease Hutchmed is preparing to file for approval of its drug for the rare disorder wAIHA in China, after chalking up a win in a pivotal phase 2/3 trial.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
